{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Participants Collected Successfully"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Participants Unable to Collect"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Number of Participants who were able to collect stem cells successfully or unable to collect after treatment with bortezomib and rituximab.","groups":[{"description":"Bortezomib 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).\n\nBortezomib: 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22.\n\nRituximab: 375 mg/m\\^2 IV on Day 8 and 22.\n\nValacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Participants Ability to Collect Stem Cells After Treatment With Bortezomib and Rituximab","type":"PRIMARY","unitOfMeasure":"Participants"}